Robert Goulet

@BiotechXGuru I'm sure Trump will probably find away to ruin tomorrow with some Iran bullshit

$ALLR as predicted it broke over $1.75 and watch for the strong momentum to break this over $2 tomorrow imo

@TaraBull dude was going easy...could of delivered a big knee

Why do people that get beat up, still keep trying to fight?

@Damaan4u33 E.... no question

Who's your pick for the worst president? A). B). C). D). or E).

@FoodPleaser what's missing is a Non Pink Chicken

Boiled Chicken, White Rice, Plain Greek Yogurt. What’s missing here? 🍗 🍚

Photo from today.

@stevemano101 @Jim_Rothman @aravind_233 I guess this would be a bullshit signal

Yeah the share awards are the issuance of new shares but I am talking about the buybacks the company has been doing including 250k shares or so in Q1 of this year. Of course, perfectly legal but just surprised that it is when the company knows what the results of the ongoing trial are and the people that they are buying back shares from do not. Just philosophical musings (ignore me)

$ALLR I just voted "for" each of the management proposals ahead of the annual meeting. Nothing to overthink here - current management is the REASON this company is turning around so not trust them doesn't make sense to me. Even regarding dilution, management has far more insight into the current state of play than us, and if they deem it necessary (in line with all other biotech nanocaps), then I trust them.

$KYTX a reminder Affiliated insider purchase: Westlake Village BioPartners (major backer) bought 133,333 shares at $7.50 in Dec 25. Bullish

@stevemano101 @Jim_Rothman @aravind_233 I believe the shares were RSU grants/awards to directors...not open market buys $allr

@Jim_Rothman @aravind_233 I genuinely can't believe biotechs like $ALLR who can confidentially see the results of their ongoing trials are allowed to buy back shares in the open market... Great as an investor but am I crazy or should this be illegal lol

@stocklllovers6 looks already well priced in, this has a very high mcap

$IBRX what happened to the days of 300% jumps when cancer breakthroughs were approved and positive? This market where everything is controlled by hedge funds and market makers is ridiculous! Retail have been suppressed and choked since the squeezes of 2021, they won’t let anything run except for their ponzi schemes that the SEC ignore!

It’s been quite a day. News coming soon re our sBLA response from FDA. Stay tuned.

Dude shows off his tattoo dedicated to chasing the bag 💰

@J_Swish24 No Seider shows this list is worthless

Top-11 defensemen in the NHL: #1 Cale Makar #2 Quinn Hughes #3 Zach Werenski #4 Lane Hutson #5 Rasmus Dahlin #6 Chuck McAvoy #7 Brock Faber #8 Jake Sanderson #9 Matthew Schaefer #10 Miro Heiskanen #11 Evan Bouchard -People’s

@Come1y @Sofia50020Sofia 😂

Possible new species. They are referred to as “Homo Slackass-Erectus” created by natural genetic evolution through constant spineless posturing and spasmatic upper limb gestures, which nes research showing to cause a shorter legs and an inability to ambulate other than in an awkward shuffling gait…😂😂😂😂

White men, what’s stopping you from dressing like this?

$crbu

@oncologytube this is not an Alisertib presentation...please fix

🧬 Is Alisertib the New Standard for Overcoming Resistance in KRAS G12C-Mutant NSCLC? 👉VIDEO: oncologytube.com/alisertib-kras… Recent data presents alisertib (elisrasib) as a potent option for both G12C-naive and refractory NSCLC patients. 🚀 Key Clinical Data: ✅ 52.9% ORR in treatment-naive patients ✅ 84% Disease Control Rate in refractory cases ✅ 15.6m Median Duration of Response for refractory patients @AACR @OncoAlert @RenoHemonc @EladSharonMD @chulkimMD @Stefani19753108 @YuZhu4 @zpyeung @TomPrt @yakkusoooooo @Molly20186 @AMRANEKarim6 @join_kana @cancerassassin1 @fireflyann @ortizaimed @Innov_Medicine @The_InnovationJ @AbiSivaMD @Davdwlkerson @YoichiKoyamaMD @KRASKickers @mybarra @ChadMoo47772206 @hirokane05 @FuturePH_Scott @gcai1978 @myfight4cancer @OncoUgi @FlyFan7 @AshleyWeiMD @15Jfco @goecp1 @oncobalaji @alejandroleonMD @everest_bio @TheAndreaSantos @drrifu @SheydaDoc @Wasim1846 #OncTwitter #LungCancer #NSCLC #KRAS #MedicalNews

@oncologytube Huh...this video is not Alisertib 🤷🏼‍♂️

WATCH: New Data on Alisertib (elisrasib) in KRAS G12C-mutant NSCLC 🫁🧬 👉 oncologytube.com/alisertib-kras… ⚡ Rapid & potent target engagement 📈 Encouraging ORR + durable responses ✅ Favorable safety & tolerability profile Promising efficacy in heavily pretreated patients — including those with acquired resistance to prior G12C inhibitors 💪 @AACR @OncoAlert @RenoHemonc @EladSharonMD @chulkimMD @Stefani19753108 @YuZhu4 @zpyeung @TomPrt @yakkusoooooo @Molly20186 @AMRANEKarim6 @join_kana @cancerassassin1 @fireflyann @ortizaimed @Innov_Medicine @The_InnovationJ @AbiSivaMD @Davdwlkerson @YoichiKoyamaMD @KRASKickers @mybarra @ChadMoo47772206 @hirokane05 @FuturePH_Scott @gcai1978 @myfight4cancer @OncoUgi @FlyFan7 @AshleyWeiMD @15Jfco @goecp1 @oncobalaji @alejandroleonMD @everest_bio @TheAndreaSantos @drrifu @SheydaDoc @Wasim1846 #KRAS #NSCLC #LungCancer #PrecisionOncology #AACR2026 #TargetedTherapy

Decent volume first hour $crbu

@RandomTheGuy_ pretty confident this never happened

Nowadays people are built different 😱

@otokyo__ Mello Yello

Give him a rap name